soul trial oral semaglutide cardiovascular outcomes trial (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine New data from the SOUL

Maintain adequate hydration by drinking sufficient fluids to produce pale yellow urine, particularly during treatment initiation and dose increases when gastrointestinal side effects are most common

Conclusions The present study provides clinical evidence for the knee arthritis-relieving benefits of Semaglutide compared to conventional pharmacological interventions against excessive BMI and its OK-associated outcomes (primarily pain and stiffness)

What happens beneath the surface is far more complex

In fact, most of what is known about microdosing for weight loss comes from real-world reports, smaller studies, and clinical practice observations

But her first go-around with the medication didnt quite stick

As research continues, its important to frame GLP-1s as a tool rather than a standalone solution to diabetes, obesity, or SUD